Navidea Biopharmaceuticals. has been granted a patent for compositions that combine a targeting moiety with a therapeutic agent, aimed at diagnosing and treating diseases caused by flaviviridae family viruses, including Zika, dengue, and yellow fever. GlobalData’s report on Navidea Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Navidea Biopharmaceuticals, Isotropically modified heterocyclic compounds was a key innovation area identified from patents. Navidea Biopharmaceuticals's grant share as of June 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of flaviviridae family virus infections
The granted patent US12005122B2 outlines a method for treating diseases caused by flaviviridae family viruses through the administration of compounds that target CD206 expressing cells. The primary focus is on a compound of Formula (II), which can be linked to one or more CD206 targeting moieties and/or chemotherapeutic agents. The claims detail various types of linkers that can be employed, including degradable, hydrolysable, and acid-sensitive linkers, as well as specific hydrocarbon chain structures for the linkers. The treatment is designed to be effective by binding to the subject's CD206 expressing cells rather than directly targeting the virus itself, thereby facilitating a reduction in the disease-causing virus.
Additionally, the patent describes methods for targeting flaviviridae viruses by specifically engaging macrophages, which are immune cells that express CD206. The claims include a range of chemotherapeutic agents that can be utilized, such as cytostatic agents, alkylating agents, and various other drug classes. The compounds may also feature a dextran backbone, enhancing their ability to bind to CD206 expressing cells. Overall, the patent presents a novel approach to treating flavivirus infections by leveraging targeted delivery mechanisms to improve therapeutic outcomes.
To know more about GlobalData’s detailed insights on Navidea Biopharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
